Skip to main content
SpringerLink
Log in

A roadmap for biomarker qualification

  • News & Views
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

A collaborative effort between pharmaceutical companies, regulatory agencies and academia to qualify biomarkers for kidney toxicity provides a model for investigating and identifying reliable safety markers for preclinical applications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Receiver operating characteristics (ROC) curve analysis.

References

  1. Dieterle, F. et al. Nat Biotechnol. 28, 463–469 (2010).

    Article  CAS  Google Scholar 

  2. Yu, Y. et al. Nat. Biotechnol. 28, 470–477 (2010).

    Article  CAS  Google Scholar 

  3. Vaidya, V.S. et al. Nat. Biotechnol. 28, 478–485 (2010).

    Article  CAS  Google Scholar 

  4. Ozer, J.S. et al. Nat. Biotechnol. 28, 486–494 (2010).

    Article  CAS  Google Scholar 

  5. Sistare, F.D. et al. Nat. Biotechnol. 28, 446–454 (2010).

    Article  CAS  Google Scholar 

  6. Dieterle, F. et al. Nat. Biotechnol. 28, 455–462 (2010).

    Article  CAS  Google Scholar 

  7. http://www.fda.gov/oc/initiatives/criticalpath/projectsummary/consortium.html

  8. http://www.fda.gov/oc/initiatives/criticalpath/

  9. Bonventre, J.V. et al. Nat. Biotechnol. 28, 436–440 (2010).

    Article  CAS  Google Scholar 

  10. Hanley, J.A. & NcNeil, B.J. Radiology 143, 29–36 (1982).

    Article  CAS  Google Scholar 

  11. The Food and Drug Administration Biomarker Qualification Review Team. Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the Predictive Safety Testing Consortium (FDA CDER, 21 February 2008).

  12. EMEA. Biomarkers Qualification: Guidance to Applicants (doc. ref. EMEA/CHMP/SAWP/72894/2008-CONSULTATION, 24 April 2008).

Download references

Author information

Authors and Affiliations

  1. David G. Warnock is in the Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA.,

    David G Warnock

  2. Department of Bioengineering and Therapeutic Sciences, Carl C. Peck is at the Center for Drug Development Science, University of California San Francisco, UC Washington Center, Washington DC, USA.,

    Carl C Peck

Authors
  1. David G Warnock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carl C Peck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to David G Warnock or Carl C Peck.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Warnock, D., Peck, C. A roadmap for biomarker qualification. Nat Biotechnol 28, 444–445 (2010). https://doi.org/10.1038/nbt0510-444

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0510-444

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation